For example, two pilot first-in-human clinical trials recently provided evidence that melanoma immunotherapy responder-derived fecal microbiota transplantation (FMT) in combination with anti-PD-1 may benefit a subset of patients with PD-1-refractory melanoma [60,61]. This evidence concerns the gene PDCD1 and melanoma.